Imunon Q1 net loss widens as R&D spending rises

Imunon

12/05/2026 13:09

Overview

U.S. biotech firm's Q1 net loss widened slightly as R&D spending increased for Phase 3 trial

Company advanced enrollment in pivotal Phase 3 OVATION 3 ovarian cancer study ahead of plan

Final Phase 2 data showed improved overall survival for lead candidate IMNN-001 in ovarian cancer

Outlook

Imunon expects enrollment in Phase 3 OVATION 3 study to complete by Q1 2029

Company says FDA is aligned with Phase 3 protocol and confirms path to BLA filing

Imunon is focusing resources on advancing the pivotal Phase 3 ovarian cancer trial

Result Drivers

TRIAL-RELATED SPENDING - Higher R&D expenses driven by costs associated with the Phase 3 OVATION 3 trial

PHASE 3 ENROLLMENT PROGRESS - Enrollment in pivotal Phase 3 OVATION 3 trial continued ahead of plan, supported by patient interest and investigator conviction

PHASE 2 SURVIVAL DATA - Final Phase 2 data showed further improvement in overall survival for IMNN-001 in ovarian cancer

Company press release: ID:nGNX6QvVng

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.84
Q1 Net Income
-$4.25 mln
Q1 Operating Expenses
$4.31 mln
Q1 Operating Income
-$4.31 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Imunon Inc is $16.00, about 486.1% above its May 11 closing price of $2.73

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)